Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Ipilimumab.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Ipilimumab.
Anthrax immune globulin, human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ipilimumab.
Advertisement
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ipilimumab.
BCG, Live, Connaught Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ipilimumab.
BCG, Live, Tice Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Ipilimumab.
Advertisement
Belimumab
The risk or severity of adverse effects can be increased when Ipilimumab is combined with Belimumab.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Ipilimumab.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Ipilimumab.
Advertisement
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ipilimumab.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Ipilimumab.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Ipilimumab.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Ipilimumab.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Ipilimumab.
Digoxin
Digoxin may decrease the cardiotoxic activities of Ipilimumab.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Ipilimumab.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Ipilimumab.
Hepatitis A Vaccine, Inactivated
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ipilimumab.
Hepatitis B Surface Antigen Vaccine
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ipilimumab.
Ouabain
Ouabain may decrease the cardiotoxic activities of Ipilimumab.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ipilimumab.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ipilimumab.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Ipilimumab.
Rabies Immune Globulin, Human
The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ipilimumab.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ipilimumab.
ROTAVIRUS VACCINE, LIVE
The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Ipilimumab.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Ipilimumab.
Salmonella enterica subsp. enterica serovar typhi
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Ipilimumab.
Tetanus Toxoid Vaccine, Inactivated
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ipilimumab.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Ipilimumab.
Typhoid Vaccine Live Ty21a
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Ipilimumab.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Ipilimumab.
Varicella Virus Vaccine Live (Oka-Merck) strain
The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Ipilimumab.
Vemurafenib
The risk or severity of increased transaminases can be increased when Vemurafenib is combined with Ipilimumab.
Yellow Fever Vaccine
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Ipilimumab.
Yellow-Fever Virus Vaccine, 17D-204 strain
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Ipilimumab.
